ClinicalTrials.gg
CompletedNCT01673724Updated Sep 15, 2017

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

A Phase 4 interventional study of pramipexole and Bromocriptine in Parkinson's Disease, sponsored by Sandoz. Completed at 7 sites in Korea, Republic of. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2017-09-15.

Sponsored by Sandoz (formerly part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.

Enrollment
19th of 26
121 · median 224
Started
2012
the only one that year
Phase 4
10 of 26
none open now
Registered
19th of 26
by date
Lead sponsor
1 of 26
Sandoz

Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 19th largest by enrollment, is the only one that started in 2012, is one of 10 in phase 4, and was the 19th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing pramipexole in Parkinson Disease as a file.
02

Study summary

The purpose of this study is to determine whether pramipexole and bromocriptine are effective in the treatment of non-motor symptoms in Parkinson's Disease.

Read the detailed description

PRIMARY OBJECTIVE Evaluate the Improvement of Nonmotor symptom scale (NMSS) between Pramipexole and Bromocriptine for early Parkinson's disease during 24-week treatment

SECONDARY OBJECTIVE

  • Evaluate the improvement for Depression which is one of the Nonmotor symptoms
  • Evaluate the improvement of clinical symptoms between two groups
  • Evaluate the improvement of Quality of Life between two groups
03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parkinson's disease patients in accordance with UK Queensquare Brain Bank
  • modified Hoehn \& Yahr stage \<3
  • Dopamine agents(Levodopa, dopamine agonists) naive patients, or the patients who have discontinued the agents at least four weeks before the screening in case of using the dopamine agents are administered before.

Exclusion criteria

Exclusion Criteria:

  • K-\<24
  • History of drug-induced Parkinsonism
  • secondary parkinsonism
  • History of schizophrenia or hallucination
  • Requirement of treatment with anti-depressants due to depressive disorder
  • Pregnant and/or breeding women
  • Renal inadequacy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Experimental
    pramipexole

    dosage form: tablet dosage: pramipexole 0.125/0.25/0.5/1mg frequency: tid duration: 24weeks

    Drug: pramipexole

  • Active comparator
    Bromocriptine

    bromocriptine dosage form: white round tablet

    Drug: Bromocriptine

Interventions

06

What researchers measure

Primary outcomes

  1. K-NMSS

    Evaluate The total and each category score of K-NMSS

    Time frame: 24 weeks

Secondary outcomes

  1. K-MADRS

    Evaluate the Improvement of the depression refering to the total score of K-MADRS

    Time frame: 24 weeks

  2. UPDRS I/II/III

    Evaluate the improvement of UPDRS I/II/III

    Time frame: 24 weeks

  3. K-PDQ39

    Evaluate the improvement of Patient's QOL

    Time frame: 24 weeks

07

Study locations

7 sites
  • Korea University Ansan Hospital
    Ansan, Korea, Republic of
  • Inje University Busan Paik Hospital
    Busan, Korea, Republic of
  • Youngnam University Hospital
    Daegu, Korea, Republic of
  • Kangwon Nat'l University Hospital
    Kangwon, Korea, Republic of
  • Inje university Sanggye Paik Hospital
    Seoul, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of May 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2012
First posted
Aug 28, 2012
Start
Feb 2012
Primary completionActual
May 23, 2016
CompletionActual
May 23, 2016
Last update
Sep 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01673724
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Aug 28, 2012
Start date
Feb 2012
Primary completion
May 23, 2016
Completion
May 23, 2016
Last update
Sep 15, 2017

Study contacts

Seongbeom Koh, MD
principal investigator · Korea University Guro Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion